홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
GDTC
#4970
CytoMed Therapeutics Limited Ordinary Shares
1.0
8
+5.88%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+5.88%
월간 변동
+35.00%
6달 변화
-46.27%
년간 변동율
-59.85%
이전 종가
1.0
2
Open
1.0
8
Bid
Ask
Low
1.0
8
High
1.0
8
양
1
마켓
주식
헬스케어
GDTC
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
11.54 M
—
Valuation ratios
Enterprise value
39.24 M
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
뉴스
STMicroelectronics株が上昇している理由;プレマーケットで動いている20銘柄
STマイクロエレクトロニクス株が上昇している理由;プレマーケットで動いている20銘柄
サイトメッド社、マレーシアでの臨床試験提携を発表し株価上昇
CytoMed stock jumps after announcing clinical trial partnership in Malaysia
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital
サイトメド・セラピューティクス、子会社に50万ドルの投資を確保
CytoMed Therapeutics secures $500,000 investment for subsidiary
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
サイトメッド、白血病治療に有望な前臨床結果を報告
CytoMed reports promising preclinical results for leukemia treatment
CytoMed Therapeutics shareholders approve all proposals at annual meeting
CytoMed Therapeutics schedules annual shareholder meeting